Nose Cleaner Salicid Obtains Clinical Approval for Sinus infection from FDA

WONJU--(Korea Newswire)--The physiological saline manufacturer Dolki Korea Ltd. (CEO Chil-Young Kim, www.salicid.com) revealed that its portable nose cleaner medical device Salicid which allows the users to produce physiological salicid themselves has obtained clinical approval from Korea FDA.

Salicid uses hypochlorous acid with strong antivirus effects to sterilize 99% of bad germs on the nose mucus and is thus effective in preventing and treating otorhinolaryngological diseases of H1N1, rhinitis, and flu.

Dolki Korea Ltd. has developed Salicid which can control the concentration of hypochlorous acid with electrolysis for the first time in the world, and has already registered 14 domestic patents and applied fir 7 foreign patents in 25 major countries across the world.

Currently there are 20 million patients with sinus infecton in the U.S. who are responsible for 6 billion dollars worth of medical bills, and 6.7% of Koreans suffer from sinus infection.

Even U.S. FDA, however, does not have drugs certified for efficacy on sinus infection. Also, in 2006 and 2007, the Fast Tract was applied to approve the clinical approval of spray-use antibiotics and antifungal drugs for sinus infection, demonstrating the recognition of this disease.

Sinus infection is an inflammatory disease from bacterial and fungal infection which begins from the congenital cause such as the structure of the nose, and has mostly been prescribed with orally-taken antibiotics so that effective treatment was hard to achieve.

Salicid, however, directly inserts through the nose the Salicid solution which kills all bacteria and fungus to remove them, thus helping relief of sinus infection.
 
Dolki Korea Ltd. is expecting good results through report study and such published on the journals of U.S. Otorhinolaryngology and Allergy and clinical cases of college hospitals of use as nose cleaners for many years on sinus infection patients.

Its CEO Chil-Young Kim has stated that “Dolki Korea Ltd. has strived for the development of Salicid for 5 years. Sinus infection treatment is a difficult area for small/mid-sized companies to challenge. Through Salicid, however, we are planning clinical application for many otorhinolaryngological diseases and mucus infection diseases with currently no treatment or many difficulties in treatment such as allergic rhinitis or periodontitis.” (Inquiries: +82-2-3461-2437, cykim7070@hanmail.net)

This is a news release distributed by Korea Newswire on behalf of this company.